Stock comparison
Corcept Therapeutics
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.41B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.27B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 77B | LMAT |
| Benjamin Graham | 86C | 89A | LMAT |
| Philip Fisher | 64C | 81C | LMAT |
| Peter Lynch | 32F | 67B | LMAT |
| Joel Greenblatt | 47D | 56D | LMAT |
| Charlie Munger | 60C | 68D | LMAT |
| Terry Smith | 68C | 69D | LMAT |
Side-by-side metrics
| Metric | CORT | LMAT |
|---|---|---|
| Market cap | $6.41B | $2.27B |
| P/E (TTM) | 122.0x | 37.1x |
| EV/EBIT | 131.9x | 36.6x |
| ROIC (TTM) | -1.23% | 9.43% |
| Gross margin | 98.25% | 72.39% |
| Net margin | 6.23% | 24.35% |
| Revenue CAGR 5y | 20.1% | 12.75% |
| EPS CAGR 5y | -0.52% | 19.04% |
| Debt / Equity | 0.0x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Debt / Equity0.0xvs 0.5x+97%
- Market cap$6.41Bvs $2.27B+65%
- Revenue CAGR 5y20.1%vs 12.75%+37%
- Gross margin98.25%vs 72.39%+26%
LMAT leads on
- ROIC (TTM)9.43%vs -1.23%+113%
- EPS CAGR 5y19.04%vs -0.52%+103%
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 6.23%+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.